

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE  
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE  
AND THE APPLICATION REVIEW SUBCOMMITTEE  
TO THE  
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: APRIL 26, 2018  
9 A.M.

REPORTER: BETH C. DRAIN, CSR  
CA CSR. NO. 7152

FILE NO.: 2018-08

133 HENNA COURT, SANDPOINT, IDAHO 83864  
208-255-5453 208-920-3543 DRAIBE@HOTMAIL.COM

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION:	
1. CALL TO ORDER.	3
2. ROLL CALL.	3
3. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS	4
4. CLOSED SESSION: DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS (HEALTH & SAFETY CODE 125290.30(F)(3)(B) AND (C)).	NONE
6. PUBLIC COMMENT.	NONE
7. ADJOURNMENT.	16

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

THURSDAY, APRIL 26, 2018

9 A.M.

CHAIRMAN THOMAS: WELCOME, EVERYBODY, TO THE REGULAR MEETING OF THE ICOC AND THE APPLICATION REVIEW SUBCOMMITTEE FOR APRIL 2018. MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: ANNE-MARIE DULIEGE.

DR. DULIEGE: YES.

MS. BONNEVILLE: DAVID HIGGINS.

DR. HIGGINS: HERE.

MS. BONNEVILLE: STEVE JUELSGAARD. SHERRY LANSING.

MS. LANSING: YES, HERE.

MS. BONNEVILLE: DAVE MARTIN.

DR. MARTIN: HERE.

MS. BONNEVILLE: LAUREN MILLER.

MS. MILLER: HERE.

MS. BONNEVILLE: ADRIANA PADILLA.

DR. PADILLA: HERE.

MS. BONNEVILLE: JOE PANETTA. FRANCISCO PRIETO. ROBERT QUINT.

DR. QUINT: PRESENT.

MS. BONNEVILLE: AL ROWLETT.

MR. ROWLETT: PRESENT.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

MS. BONNEVILLE: JEFF SHEEHY.  
SUPERVISOR SHEEHY: PRESENT.  
MS. BONNEVILLE: OS STEWARD.  
DR. STEWARD: HERE, LITERALLY.  
MS. BONNEVILLE: JONATHAN THOMAS.  
CHAIRMAN THOMAS: HERE.  
MS. BONNEVILLE: ART TORRES.  
MR. TORRES: HERE.  
MS. BONNEVILLE: DIANE WINOKUR.  
DR. MELMED: SHLOMO MELMED. I'M HERE.  
MS. BONNEVILLE: THANK YOU. ARE THERE  
OTHER MEMBERS OF THE BOARD THAT I DID NOT CALL?  
MR. BURTIS: YES. THIS IS KEN BURTIS AT  
UC DAVIS.  
MS. BONNEVILLE: THANKS, KEN.  
DIANE, ARE YOU ON THE CALL? IF YOU ARE,  
WE CAN'T HEAR YOU. YOU MIGHT BE ON MUTE.  
MR. TORRES: SHE WAS ON THE CALL A MOMENT  
AGO.  
MS. WINOKUR: I AM ON THE CALL.  
MS. BONNEVILLE: THANKS, DIANE. ALL  
RIGHT.  
CHAIRMAN THOMAS: THANK YOU, MARIA.  
WE'RE GOING TO GO TO ITEM 3, CONSIDERATION OF  
APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL

1 STAGE PROJECTS. AND WE'LL TURN IT OVER HERE TO  
2 SUPERVISOR SHEEHY.

3 SUPERVISOR SHEEHY: THANK YOU, CHAIRMAN  
4 THOMAS.

5 ARE YOU PRESENTING TODAY, DR. SAMBRANO?

6 DR. SAMBRANO: YES, I AM. THANK YOU VERY  
7 MUCH, MR. SHEEHY.

8 JUST SO YOU ALL KNOW, I HAVE WITH ME DR.  
9 SHYAM PATEL FROM THE REVIEW TEAM TO HELP ME ADDRESS  
10 ANY QUESTIONS SHOULD THEY ARISE. AMY IS AT THE  
11 MOMENT LOOKING FOR THE SLIDES TO PUT UP, BUT WE CAN  
12 CERTAINLY GET STARTED WITHOUT THEM.

13 SO TODAY WE'RE BRINGING FOR YOUR  
14 CONSIDERATION THREE APPLICATIONS RESPONDING TO OUR  
15 CLINICAL STAGE PROGRAM. SO THIS IS CLIN2. THEY ALL  
16 HAPPEN TO BE CLIN2, CLINICAL TRIAL APPLICATIONS.

17 A REMINDER OF THE SCORING SYSTEM THAT WE  
18 USE JUST SO YOU HAVE CLARITY ON WHAT THE  
19 RECOMMENDATIONS MEAN. WE SCORE THESE APPLICATIONS  
20 AS 1, 2, OR A 3, WITH THE 1 MEANING THAT IT HAS  
21 EXCEPTIONAL MERIT AND WARRANTS FUNDING; A SCORE OF 2  
22 MEANS IT NEEDS IMPROVEMENT AND CAN BE RESUBMITTED TO  
23 ADDRESS THOSE AREAS OF IMPROVEMENT; AND A SCORE OF 3  
24 MEANS IT IS SUFFICIENTLY FLAWED THAT IT SHOULD NOT  
25 BE RESUBMITTED FOR AT LEAST SIX MONTHS. SO THAT'S

1 THE SCORING SYSTEM WE USE.

2 THE FIRST APPLICATION TO BE CONSIDERED IS  
3 CLIN2-10830, AND THIS IS AN APPLICATION --

4 SUPERVISOR SHEEHY: GIL, CAN I TAKE THEM  
5 OUT OF ORDER? CAN WE START WITH 10846 PLEASE?

6 DR. SAMBRANO: SURE. SO CLIN2-10846. SO  
7 THIS ONE IS A PHASE 1 CLINICAL TRIAL OF A CAR-T CELL  
8 THERAPY FOR B CELL CANCERS. SO THE THERAPY IS A  
9 T-CELL OR T-CELLS THAT ARE GENETICALLY ENGINEERED TO  
10 TARGET CD 19 AND/OR CD 22 ON CANCER B CELLS. AND  
11 THIS IS OBVIOUSLY FOR PATIENTS THAT HAVE A RELAPSED  
12 OR REFRACTORY B CELL CANCER.

13 THE GOAL OF THE PROJECT IS TO COMPLETE A  
14 PHASE 1 TRIAL TO ASSESS THE SAFETY AND FEASIBILITY  
15 OF THIS THERAPEUTIC APPROACH. THE FUNDS REQUESTED  
16 FOR THIS APPLICATION ARE 11.9 MILLION. THE  
17 APPLICANTS ARE PROVIDING 2.3 MILLION IN CO-FUNDING  
18 FOR THIS PROJECT.

19 THE GWG RECOMMENDED THIS APPLICATION WITH  
20 A SCORE OF 1. THERE WERE 13 MEMBERS WHO VOTED WITH  
21 A SCORE OF 1; THERE WAS ONE MEMBER THAT GAVE IT A  
22 SCORE OF 2; AND NONE A SCORE OF 3. THE CIRM TEAM  
23 ALSO RECOMMENDS FUNDING OF THIS APPLICATION IN THE  
24 AWARD AMOUNT OF \$11.9 MILLION. MR. SHEEHY.

25 SUPERVISOR SHEEHY: THANK YOU, DR.

1 SAMBRANO.

2 DO I HAVE A MOTION TO ACCEPT THE CIRM TEAM  
3 RECOMMENDATION AND FUND THIS APPLICATION?

4 MS. LANSING: I'LL MOVE IT.

5 MR. TORRES: SECOND.

6 SUPERVISOR SHEEHY: GOT A SECOND. IS  
7 THERE ANY BOARD DISCUSSION? ANY PUBLIC COMMENT AT  
8 ANY SITE? COULD WE CALL THE ROLL THEN PLEASE.

9 MS. BONNEVILLE: SURE.

10 ANNE-MARIE DULIEGE.

11 DR. DULIEGE: YES.

12 MS. BONNEVILLE: DAVID HIGGINS.

13 DR. HIGGINS: YES.

14 MS. BONNEVILLE: SHERRY LANSING.

15 MS. LANSING: YES.

16 MS. BONNEVILLE: DAVE MARTIN.

17 DR. MARTIN: YES.

18 MS. BONNEVILLE: LAUREN MILLER.

19 MS. MILLER: YES.

20 MS. BONNEVILLE: ADRIANA PADILLA.

21 DR. PADILLA: YES.

22 MS. BONNEVILLE: JOE PANETTA. FRANCISCO  
23 PRIETO.

24 DR. PRIETO: AYE.

25 MS. BONNEVILLE: ROBERT QUINT.

1 DR. QUINT: YES.  
2 MS. BONNEVILLE: AL ROWLETT.  
3 MR. ROWLETT: YES.  
4 MS. BONNEVILLE: JEFF SHEEHY.  
5 SUPERVISOR SHEEHY: YES.  
6 MS. BONNEVILLE: OS STEWARD.  
7 DR. STEWARD: YES.  
8 MS. BONNEVILLE: JONATHAN THOMAS.  
9 CHAIRMAN THOMAS: YES.  
10 MS. BONNEVILLE: ART TORRES.  
11 MR. TORRES: AYE.  
12 MS. BONNEVILLE: DIANE WINOKUR.  
13 MS. WINOKUR: YES.  
14 MS. BONNEVILLE: MOTION CARRIES.  
15 SUPERVISOR SHEEHY: GREAT. THANK YOU. SO  
16 DR. SAMBRANO.  
17 MS. LANSING: I'LL STAY ON FOR A WHILE AND  
18 JUST LISTEN.  
19 MS. BONNEVILLE: THANK YOU.  
20 MS. LANSING: I'LL PUT IT ON MUTE, BUT  
21 I'LL LISTEN FOR A WHILE.  
22 SUPERVISOR SHEEHY: DR. SAMBRANO, WOULD  
23 YOU LIKE TO RETURN TO 10830 IS THE NEXT ONE.  
24 DR. SAMBRANO: OKAY. VERY WELL. SO  
25 CLIN2-10830. THIS IS A PROJECT INTENDING TO CONDUCT

1 A PHASE 1 CLINICAL TRIAL OF A THERAPY FOR  
2 ARTEMIS-SCID.

3 SO THE THERAPY IS GENE CORRECTION OF BLOOD  
4 STEM CELLS AND TRANSPLANTATION OF THOSE  
5 AUTOLOGOUSLY. THE INDICATION IS FOR CHILDREN THAT  
6 HAVE SEVERE COMBINED IMMUNODEFICIENCY OR SCID THAT  
7 IS DUE TO THE ARTEMIS GENE DEFECT.

8 THEIR GOAL IS TO COMPLETE A PHASE 1  
9 CLINICAL TRIAL TO ASSESS THE SAFETY AND FEASIBILITY  
10 OF THIS THERAPY. THE REQUEST IS 12 MILLION BY THE  
11 APPLICANT. NO CO-FUNDING IS REQUIRED AND NONE IS  
12 BEING PROVIDED IN THIS PARTICULAR CASE.

13 THE GWG RECOMMENDATION IS A SCORE OF 1.  
14 THIS WAS UNANIMOUS, 15 GWG MEMBERS GIVING IT A SCORE  
15 OF 1. THE CIRM TEAM CONCURS WITH THIS  
16 RECOMMENDATION AND SUGGESTS FUNDING IN THE AWARD  
17 AMOUNT OF 12 MILLION. MR. SHEEHY.

18 SUPERVISOR SHEEHY: THANK YOU. DO I HAVE  
19 A MOTION TO ACCEPT THE CIRM TEAM RECOMMENDATION AND  
20 FUND THIS APPLICATION?

21 DR. PRIETO: SO MOVED.

22 SUPERVISOR SHEEHY: DO I HAVE A SECOND?

23 MS. WINOKUR: SECOND.

24 SUPERVISOR SHEEHY: IS THERE ANY BOARD  
25 COMMENT OR QUESTIONS? IS THERE ANY PUBLIC COMMENT?

1 CAN WE CALL THE ROLL.  
2 MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
3 DR. DULIEGE: YES.  
4 MS. BONNEVILLE: DAVID HIGGINS.  
5 DR. HIGGINS: YES.  
6 MS. BONNEVILLE: DAVE MARTIN.  
7 DR. MARTIN: YES.  
8 MS. BONNEVILLE: LAUREN MILLER.  
9 MS. MILLER: YES.  
10 MS. BONNEVILLE: ADRIANA PADILLA.  
11 DR. PADILLA: YES.  
12 MS. BONNEVILLE: FRANCISCO PRIETO.  
13 DR. PRIETO: AYE.  
14 MS. BONNEVILLE: ROBERT QUINT.  
15 DR. QUINT: YES.  
16 MS. BONNEVILLE: AL ROWLETT.  
17 MR. ROWLETT: YES.  
18 MS. BONNEVILLE: JEFF SHEEHY.  
19 SUPERVISOR SHEEHY: YES.  
20 MS. BONNEVILLE: OS STEWARD.  
21 DR. STEWARD: YES.  
22 MS. BONNEVILLE: JONATHAN THOMAS.  
23 CHAIRMAN THOMAS: YES.  
24 MS. BONNEVILLE: ART TORRES.  
25 MR. TORRES: AYE.

1 MS. BONNEVILLE: DIANE WINOKUR.

2 MS. WINOKUR: YES.

3 MS. BONNEVILLE: MOTION CARRIES.

4 SUPERVISOR SHEEHY: THANK YOU. DR.

5 SAMBRANO, THE LAST APPLICATION PLEASE.

6 DR. SAMBRANO: OKAY. THE LAST APPLICATION

7 IS CLIN2-11031. AND SO THIS IS FOR A PHASE 1/2

8 CLINICAL TRIAL OF A THERAPY FOR BETA-THALASSEMIA.

9 SO THIS THERAPY IS A GENE CORRECTION OF  
10 AUTOLOGOUS BLOOD STEM CELLS AND TRANSPLANTATION OF  
11 THOSE INTO PATIENTS WITH TRANSFUSION-DEPENDENT  
12 BETA-THALASSEMIA.

13 THE GOAL OF THIS PROJECT IS TO COMPLETE A  
14 PHASE 1/2 TRIAL TO ASSESS SAFETY, ACTIVITY, AND  
15 EFFICACY OF THE THERAPY. THE FUNDS REQUESTED ARE \$8  
16 MILLION. THE APPLICANT IS PROVIDING 14.9 MILLION IN  
17 CO-FUNDING TO THIS PROJECT.

18 THE GRANTS WORKING GROUP RECOMMENDATION IS  
19 ALSO A UNANIMOUS RECOMMENDATION OF 1 WITH 12 MEMBERS  
20 GIVING IT THAT SCORE. THE CIRM TEAM RECOMMENDATION  
21 CONCURS WITH THAT OF THE GWG, AND WE RECOMMEND  
22 FUNDING IN THE AWARD AMOUNT OF 8 MILLION.

23 MR. SHEEHY.

24 SUPERVISOR SHEEHY: THANK YOU, DR.

25 SAMBRANO.

1 DO I HAVE A MOTION TO ACCEPT THE CIRM TEAM  
2 RECOMMENDATION FROM THIS APPLICATION?

3 MR. TORRES: SO MOVED.

4 SUPERVISOR SHEEHY: DO I HAVE A SECOND?

5 DR. PRIETO: SECOND.

6 SUPERVISOR SHEEHY: THANK YOU. DO WE HAVE  
7 ANY BOARD COMMENT OR QUESTIONS?

8 DR. DULIEGE: MAYBE A BRIEF COMMENT FROM  
9 ME AND A QUESTION. I SENSE THAT FROM ALL THESE  
10 APPLICATIONS THE TOPIC WAS SO IMPORTANT MEDICALLY  
11 AND THE SCORING FROM THE GWG GROUP WAS SO CLEAR THAT  
12 THIS DOESN'T LEAD TO A LOT OF QUESTIONS, IN FACT,  
13 ANY QUESTIONS.

14 MY QUESTION IS AT WHAT POINT WILL WE  
15 DISCUSS THE IMPACT OF ALL THESE APPROVALS ON THE  
16 TOTAL BUDGET LEFT FOR GRANTING?

17 DR. SAMBRANO: THAT'S A GREAT QUESTION.  
18 SO WE DO WANT TO KEEP YOU UP TO DATE ON THAT. SO  
19 ASSUMING THAT WE FUND THESE THREE PROJECTS, WE ARE  
20 NEARING 65 MILLION IN TERMS OF WHAT WOULD HAVE BEEN  
21 ALLOCATED. OUR ANNUAL BUDGET IS 130 MILLION. SO  
22 WE'D BE ABOUT HALFWAY OR NEARLY HALFWAY.

23 DR. DULIEGE: THANK YOU FOR THIS  
24 CLARIFICATION. I DON'T HAVE SPECIFIC QUESTION ON  
25 THE APPLICATION ITSELF. IT WAS VERY

1 STRAIGHTFORWARD.

2 DR. STEWARD: JUST FOR THE RECORD, COULD  
3 YOU SAY HOW MANY CLINICAL TRIALS THIS BRINGS US WITH  
4 THE FUNDING OF THESE? I THINK IT MIGHT BE CLOSE TO  
5 48 OR SOMETHING LIKE THAT.

6 DR. SAMBRANO: TOTAL. YES. CORRECT.

7 DR. STEWARD: THANKS.

8 DR. MARTIN: I HAVE ANOTHER QUESTION  
9 THAT'S SORT OF IN THAT SAME CAMP. AND THAT IS -- OR  
10 ACTUALLY JUST TAKE THIS ONE FIRST, AND MAYBE YOU CAN  
11 ANSWER IT LATER. BUT WHAT HAS BEEN THE TIME LAPSED  
12 FROM THIS FIRST -- THE DATE OF SUBMISSION OF THE  
13 APPLICATION UNTIL, NOT JUST THIS VOTE, BUT BEFORE  
14 THE CHECK CLEARS?

15 DR. SAMBRANO: SO TYPICALLY -- WELL, YOU  
16 ARE ASKING FROM THE TIME THAT THEY APPLY UNTIL THEY  
17 GET THEIR FIRST -- THE AWARD START. IS THAT THE  
18 QUESTION?

19 DR. MARTIN: BECAUSE SEVERAL OF THESE I  
20 NOTICED ACTUALLY ARE REAPPLICATIONS AFTER THEY HAVE  
21 ADDRESSED SOME OF THE CONCERNS OF THE GROUP  
22 INITIALLY. I'M JUST INTERESTED BECAUSE I THINK -- I  
23 EXPECT IT'S GOING TO BE AN IMPRESSIVE NUMBER.

24 DR. SAMBRANO: RIGHT. SO THE TYPICAL  
25 CYCLE FOR A CLINICAL REVIEW IS ABOUT THREE MONTHS

1 FROM THE TIME OF APPLICATION UP TO THE TIME THAT IT  
2 GETS TO THE BOARD, ASSUMING THAT THERE IS NO  
3 RESUBMISSION. IN THE CASES WHERE THERE IS A  
4 RESUBMISSION, THAT MEANS THAT THE APPLICATION  
5 PROBABLY TAKES FIVE MONTHS FROM THE TIME OF  
6 APPLICATION TO THE TIME IT COMES TO THE BOARD.

7 DR. MARTIN: IF YOU WOULD JUST SEND ME AN  
8 E-MAIL. I'M INTERESTED IN THESE SPECIFIC ONES  
9 BECAUSE THEY WERE SO CLEARLY VERY POSITIVE REVIEWS  
10 ON THE FINAL REVIEW. AS I RECALL, AT LEAST TWO OF  
11 THEM, THESE WERE RESUBMISSIONS. AND SO THE PROCESS  
12 IS OBVIOUSLY WORKING, BUT I REALLY AM INTERESTED  
13 SPECIFICALLY IN KNOWING.

14 DR. SAMBRANO: OKAY. CERTAINLY.

15 DR. MARTIN: THANK YOU.

16 DR. PATEL: JUST TO ADD, AFTER THE AWARD  
17 HAS BEEN APPROVED BY THE BOARD, THE CONTRACTING  
18 PROCESS LASTS 45 DAYS. SO CHECK IN HAND WOULD BE 45  
19 DAYS AFTER APPROVAL BY THE BOARD.

20 DR. MARTIN: THANK YOU.

21 SUPERVISOR SHEEHY: IS THERE ADDITIONAL  
22 BOARD COMMENT OR QUESTIONS? ANY PUBLIC COMMENT AT  
23 ANY OF THE SITES? CAN WE CALL THE ROLL.

24 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

25 DR. DULIEGE: YES.

1 MS. BONNEVILLE: DAVID HIGGINS.  
2 DR. HIGGINS: YES.  
3 MS. BONNEVILLE: DAVE MARTIN.  
4 DR. MARTIN: YES.  
5 MS. BONNEVILLE: LAUREN MILLER.  
6 MS. MILLER: YES.  
7 MS. BONNEVILLE: ADRIANA PADILLA.  
8 DR. PADILLA: YES.  
9 MS. BONNEVILLE: FRANCISCO PRIETO.  
10 DR. PRIETO: AYE.  
11 MS. BONNEVILLE: ROBERT QUINT.  
12 DR. QUINT: YES.  
13 MS. BONNEVILLE: AL ROWLETT.  
14 MR. ROWLETT: YES.  
15 MS. BONNEVILLE: JEFF SHEEHY.  
16 SUPERVISOR SHEEHY: YES.  
17 MS. BONNEVILLE: OS STEWARD.  
18 DR. STEWARD: YES.  
19 MS. BONNEVILLE: JONATHAN THOMAS.  
20 CHAIRMAN THOMAS: YES.  
21 MS. BONNEVILLE: ART TORRES.  
22 MR. TORRES: AYE.  
23 MS. BONNEVILLE: DIANE WINOKUR.  
24 MS. WINOKUR: YES.  
25 MS. BONNEVILLE: MOTION CARRIES.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

SUPERVISOR SHEEHY: THANK YOU. CHAIRMAN THOMAS, THIS CONCLUDES THE BUSINESS OF THE APPLICATION REVIEW SUBCOMMITTEE.

CHAIRMAN THOMAS: THANK YOU, MR. SUPERVISOR. THE ONLY ITEM LEFT IS ARE THERE ANY MEMBERS OF THE PUBLIC WHO WOULD LIKE TO COMMENT ON ANY TOPIC? HEARING NONE, THAT WOULD CONCLUDE TODAY'S MEETING. THANK YOU VERY MUCH, EVERYBODY. AND OUR NEXT MEETING WILL BE THE APPLICATION REVIEW SUBCOMMITTEE AND FULL BOARD MEETING TELEPHONICALLY IN MAY. THANK YOU, EVERYBODY, FOR YOUR PARTICIPATION AS ALWAYS. WE STAND ADJOURNED.

(THE MEETING WAS THEN CONCLUDED AT 9:21 AM.)

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON APRIL 26, 2018, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152  
133 HENNA COURT  
SANDPOINT, IDAHO  
(208) 255-5453